Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Regulation of Amyloid Precursor Protein Processing by Serotonin Signaling

Abstract

Proteolytic processing of the amyloid precursor protein (APP) by the β- and γ-secretases releases the amyloid-β peptide (Aβ), which deposits in senile plaques and contributes to the etiology of Alzheimer's disease (AD). The α-secretase cleaves APP in the Aβ peptide sequence to generate soluble APPα (sAPPα). Upregulation of α-secretase activity through the 5-hydroxytryptamine 4 (5-HT4) receptor has been shown to reduce Aβ production, amyloid plaque load and to improve cognitive impairment in transgenic mouse models of AD. Consequently, activation of 5-HT4 receptors following agonist stimulation is considered to be a therapeutic strategy for AD treatment; however, the signaling cascade involved in 5-HT4 receptor-stimulated proteolysis of APP remains to be determined. Here we used chemical and siRNA inhibition to identify the proteins which mediate 5-HT4d receptor-stimulated α-secretase activity in the SH-SY5Y human neuronal cell line. We show that G protein and Src dependent activation of phospholipase C are required for α-secretase activity, while, unexpectedly, adenylyl cyclase and cAMP are not involved. Further elucidation of the signaling pathway indicates that inositol triphosphate phosphorylation and casein kinase 2 activation is also a prerequisite for α-secretase activity. Our findings provide a novel route to explore the treatment of AD through 5-HT4 receptor-induced α-secretase activation.

Citation: Pimenova AA, Thathiah A, De Strooper B, Tesseur I (2014) Regulation of Amyloid Precursor Protein Processing by Serotonin Signaling. PLoS ONE 9(1): e87014. https://doi.org/10.1371/journal.pone.0087014

Editor: Bart Dermaut, Pasteur Institute of Lille, France

Received: September 16, 2013; Accepted: December 16, 2013; Published: January 21, 2014

Copyright: © 2014 Pimenova et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Fund for Scientific Research Flanders, KU Leuven, Federal Office for Scientific Affairs (IAP P7/16), a Methusalem grant of the Flemish Government, VIB, IWT. BDS is the Arthur Bax and Anna Vanluffelen chair for Alzheimer's disease. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Bart De Strooper is a consultant for Janssen Pharmaceutica (Beerse, Belgium), Remynd NV (Leuven, Belgium) and Envivo Inc (Boston, USA). The authors have declared that this does not alter their adherence to all the PLOS ONE policies on sharing data and materials. The authors have no direct or indirect financial interest in the current study. The authors have declared that no competing interests exist.

Introduction

The most common form of dementia in elderly people is Alzheimer's disease (AD), which is pathologically characterized by progressive neuronal loss and deposition of the amyloid-β peptide (Aβ) in amyloid plaques. Current therapeutic targets are the β- and γ-secretases, which generate Aβ from amyloid precursor protein (APP). Several drugs inhibiting or modulating the activity of these secretases have failed in clinical trials due to severe side effects or to difficulty in delivery through the blood brain barrier [1]. APP is also cleaved by a third secretase called α-secretase. The α-secretase cleaves APP within the Aβ peptide sequence, producing a soluble APPα fragment (sAPPα), which precludes Aβ generation. Indeed, in vivo overexpression or upregulation of α-secretase activity in mice indicate that α-secretase activation leads to a decrease in Aβ production and a reduction in the amyloid plaque load in AD mouse models [2], [3]. These effects were accompanied by an improvement in the cognitive deficits, providing considerable support for modulation of α-secretase activity as a viable strategy in the fight against AD [2], [3].

To specifically target the non-amyloidogenic pathway of APP processing, a fundamental consideration would be to understand the mechanism of α-secretase activation and to determine the signaling cascade of kinases and second messengers that directly regulate α-secretase-mediated proteolysis of APP. These molecules can be directly targeted pharmacologically, but also indirectly via G protein-coupled receptors (GPCR), such as the muscarinic, glutamatergic and serotonergic receptors. In particular, the G protein coupled 5-hydroxytryptamine 4 (5-HT4) receptor is gaining considerable interest as a modulator of α-secretase activity due to its role in memory and learning and regulation of APP processing [4]. Activation of the 5-HT4 receptor leads to an increase in the population spike amplitude in the hippocampal CA1 region, and this effect persists in a transgenic mouse model of AD [5], [6], suggesting that 5-HT4 receptor-mediated signaling remains functional under these pathological conditions. On the other hand, agonist stimulation of the 5-HT4 receptor results in increased sAPPα secretion with a concomitant decrease in Aβ peptide levels in primary neuronal cultures and an alleviation of amyloid plaque load in AD mouse models [7]–[9]. Such amelioration of disease pathology is correlated with improvements in memory and learning in behavioral paradigms and scopolamine-induced models of cognitive deficit [10]–[12]. Additionally, an increase in acetylcholine release is observed after 5-HT4 receptor agonist application in vivo [13]. This could be a valuable property when considering 5-HT4 receptor agonists for AD treatment, which could complement the currently licensed therapy of cholinesterase inhibition for partial symptomatic relief [14].

Despite numerous reports on 5-HT4 receptor function in memory and learning and its effect on APP processing, the downstream signaling pathway responsible for this 5-HT4 receptor-mediated effect is still poorly understood. 5-HT4 receptor stimulation results in an accumulation of cAMP, a second messenger required for protein kinase A (PKA) and exchange protein activated by cAMP (Epac) activation. However, 5-HT4 receptor-mediated non-amyloidogenic processing of APP occurs independently of PKA activation, but can be regulated by Epac1 activation of Rac1 and Rap signaling in cell lines and primary neurons [15]. The 5-HT4 receptor is constitutively bound to the Src non-receptor tyrosine kinase, which is required for ERK activation [16]. In addition, 5-HT4 receptor stimulation in adrenocortical cells and cardiomyocytes results in an increase of calcium influx, which results in activation of voltage-gated calcium channels through PKA [17], [18]. It is unknown whether these latter pathways also contribute to α-secretase activation downstream of the 5-HT4 receptor. Altogether, these studies suggest a complicated picture of the downstream signaling pathways involved in 5-HT4 receptor stimulation and reveal the importance of delineation of the mechanism of 5-HT4 receptor-mediated APP proteolysis.

Finally, several metalloproteinases have been proposed as α-secretase; however, the identity of 5-HT4 receptor-induced α-secretase activity has not been fully addressed. The disintegrin and metalloprotease ADAM10, a major constitutive α-secretase of APP [19], [20], is a feasible candidate [21]. However, ADAM17 is more likely to be the inducible APP α-secretase based on studies which have investigated the regulated ectodomain shedding of other ADAM substrates after protein kinase C (PKC) activation [22]. In support of this is the observation that M1 receptor induced sAPPα release correlates with increased ADAM17 expression levels [23]. Nevertheless, additional metalloproteinases, such as meprin β and membrane-type matrix metalloproteinases, were shown to mediate α-cleavage of APP [24], [25].

Here, we specifically determined the intracellular signaling cascade involved in 5-HT4d receptor stimulation and inducible α-secretase activity. We used human SH-SY5Y neuroblastoma cells to analyze APP processing for practical reasons and experimental consistency. Human SH-SY5Y cells can generate sustainable cells with characteristics that resemble the morphology and biochemistry of mature neurons [26]. We present evidence that the G protein-dependent pathway activating Src, phospholipase C (PLC) and casein kinase 2 (CK2) is responsible for the 5-HT4d receptor-stimulated induction of α-secretase activity. Interestingly and in contrast to previous publications, we find that adenylyl cyclase (AC) and cAMP signaling are not required for 5-HT4d receptor-mediated α-secretase activity [15]. Furthermore, we analyzed the reported α-secretases as putative mediators of the 5-HT4d receptor effect on APP shedding using RNAi studies.

Materials and Methods

Reagents and Antibodies

Tissue culture reagents were purchased from Invitrogen. GF109203X, SQ22536, D609, ionomycin, 4,5,6,7-tetrabromo-1H-benzotriazole (TBB), GR113808, NF449, gallein and batimastat were obtained from Tocris. 5-hydroxytryptamine (5-HT), cholera toxin B (CTB) and chlorogenic acid (CGA) were from Sigma-Aldrich. Phorbol 12-myristate 13-acetate (PMA), 2,5-dideoxyadenosine (DDA), IP3K inhibitor, TAPI-1 and GM6001 were obtained from Calbiochem/VWR. Bosutinib was from Selleck. Prucalopride was kindly provided by Movetis (NV, Turnhout, Belgium). Table 1 summarizes the known potencies of the used agonists and antagonists. Following antibodies were purchased: CK2 α (H-286) from Santa Cruz, MMP-9 (G657) and ADAM9 (2099) from Cell Signaling, ADAM17 (T5442) and β-Actin (A5441) from Sigma-Aldrich. ADAM10 (B42) and APP (B63) antibodies were made in house and previously described [27]. Gαs dominant negative construct was previously described (pcDNAI-Amp-GαsDN, [28]).

thumbnail
Download:
Table 1. Overview of agonists, antagonists and inhibitors used to investigate the proteins contributing to the induction of sAPPα after 5-HT4d receptor stimulation.

https://doi.org/10.1371/journal.pone.0087014.t001

Inhibitor treatment and soluble APP analysis (SEAP assay)

SH-SY5Y human neuroblastoma cells (CRL-2266, ATCC) were cultured in DMEM/F12 supplemented with 10% fetal bovine serum (FBS). For analysis of soluble APP secretion, a mix of 1,5 µg plasmid encoding human wild type APP695 linked to Alkaline Phosphatase (AP-APP) at the N-terminus (pEAK12-AP-APP, [29]), 1,35 µg of 5-HT4d receptor isoform in pcDNA3.1 (pcDNA3.1-5-HT4d, kindly provided by Joris De Mayer and Jan Schuurkes, Movetis, Turnhout, Belgium) and 0,15 µg of GFP (pmaxFP-Green-N, Amaxa) was prepared in OPTI-MEM and combined with 20 µl of Lipofectamine 2000 (Invitrogen). After 20 minutes incubation at room temperature transfection mix was combined with a trypsinized cell suspension in growth medium containing 10% FBS. After another 15 minutes incubation at room temperature cells were seeded in a 96-well plate at 80.000 cells/well. The next day medium was changed to DMEM/F12 supplemented with 5% dialyzed FBS (10,000 molecular weight cutoff), which is devoid of serotonin otherwise present in undialyzed FBS that causes 5-HT4 receptor desensitization. After three days, cells were washed and incubated in serum free medium (SFM) for another 24 hours. Next cells were stimulated with 1 µM of the following compounds: prucalopride, 5-HT, PMA and GR113808 in SFM for 24 hours and the conditioned medium was analyzed for secreted AP (SEAP) activity with Great EscAPe SEAP Chemiluminescence Kit 2.0 (Clontech) according to manufacturer's instructions. Luminescence was measured with the EnVision® multilabel reader (PerkinElmer). For signaling studies dilution curves of inhibitory compounds were made in combination with induction by 1 µM prucalopride or 5-HT. DMSO incubation was used as a control in all experiments carried out. The ratio of individual luminescence counts from the tested conditions to the mean value of DMSO treated cells was plotted as SEAP fold induction. Cells were used for the MTS proliferation assay (CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay) and the LDH cytotoxicity assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay) according to manufacturer's instructions (Promega). Compound dilution curves were performed in the range of the reported effective concentrations (Table 1) and working concentrations were determined in the SEAP assay as those giving significant inhibition of 5-HT4d receptor-stimulated sAPPα secretion. MTS and LDH assays were used to define working concentrations of the different compounds that were non-toxic to the cells.

cAMP assay

cAMP levels were assessed using the Alphascreen® cAMP assay kit (PerkinElmer Life Sciences). 2,88·106 or 1·106 SH-SY5Y cells were seeded in T75 or T25 flasks, respectively. Adherent cells were transfected after 4 hours with Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer's instructions. A mix of 7,5 µg pEAK12-AP-APP, 6 µg pcDNA3.1-5-HT4d and 1,5 µg pmaxFP-Green-N plasmids (ratio of 5∶4∶1) was used for transfection in T75 flasks. A mix of 1,25 µg pEAK12-AP-APP, 0,65 µg pcDNA3.1-5-HT4d receptor and 2,6 µg pcDNAI-Amp-GαsDN or pcDNA3.1 as an empty vector control (ratio of 2∶1∶4) was used for transfection in T25 flasks. 3 hours later transfection mixes were replaced with growth medium for 16 hours and cells were treated with medium supplemented with 5% dialyzed FBS and SFM as described under “inhibitor treatment and soluble APP analysis”. Then cells were gently dissociated with Versene solution (Invitrogen) to obtain a single cell suspension. Next cells were counted to determine the exact cell number. Equal numbers of cells were combined with the acceptor beads coupled to an anti-cAMP antibody and biotinylated cAMP, both provided in the Alphascreen® cAMP assay kit (PerkinElmer Life Sciences), and a serial dilution of compound. After incubating the cells for one hour, streptavidin-donor beads were added and the cells were permeabilized with 0,3% Tween-20 for 30 minutes, which released intracellular cAMP. The assay is based on competition between endogenously produced cAMP by the stimulated cells and exogenously added biotinylated cAMP. The electron transfer between donor and acceptor beads was measured with the EnVision® multilabel reader (PerkinElmer). DMSO was diluted to a final concentration of 0,1% and kept equal in all samples to avoid differential effects of different DMSO concentrations on the cells. cAMP concentrations were determined using a standard curve.

Calcium measurements

Calcium imaging was assessed using the Fluo-4 NW calcium assay kit (Invitrogen). SH-SY5Y cells were transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d receptor and pmaxFP-Green-N in Optilux black wall clear bottom plates (BD Biosciences) and treated as described under “inhibitor treatment and soluble APP analysis”. Next cells were loaded with Fluo-4 NW dye mix according to manufacturer's instructions. Binding with calcium ions increases fluorescence of the dye. Baseline fluorescence of the dye was recorded at the steady state, while stimulated calcium release was assessed after automated addition of the compounds at different time points using IN Cell Analyzer 2000 (GE Healthcare). Calcium images were analyzed using the “Plot Z-axis Profile” function of ImageJ (NIH). Data are presented as a ratio of fluorescence intensity of Fluo-4 NW at any given time to baseline fluorescence (F/F0).

Construction of mutated cDNA

Mutations in the cDNA of the 5-HT4d receptor were introduced using the QuickChange II XL site-directed mutagenesis kit from Stratagene. All vector modifications were validated with sequencing using BigDye® Terminator v3.1 Cycle Sequencing and the ABI Prism® 3100 Genetic Analyzer (Applied Biosystems). Obtained data were analyzed with the Sequence Scanner program and LALIGN tool from ch.embnet.org.

siRNA-mediated knockdown and immunoblotting

Knockdown of the proteins of interest was performed 4 hours after SH-SY5Y cells were transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d receptor and pmax-FP-Green-N plasmids. Half of the medium was replaced with transfection mix containing 3 nM target protein siRNA and Lipofectamine RNAiMAX (Invitrogen) and left on the cells overnight. Next we proceeded with the protocol as described under “inhibitor treatment and soluble APP analysis”. The following siRNAs were used: Stealth RNAi™ siRNAs were used for GNAS HSS104240, GNAQ HSS104237, GNA13 HSS173827, PLCG1 HSS108094, CSNK2A1 HSS175396, ADAM9 HSS189548, MMP9 HSS181135 and BLOCK-iT™ Alexa Fluor® Red Fluorescent Oligo as a control (Invitrogen). The siGENOME SMARTpool was used for ADAM10 and siGENOME Non-Targeting siRNA Pool #1 as a control (Dharmacon). The FlexiTube GeneSolution GS6868 SI02664501 was used for ADAM17 and AllStars Negative Control siRNA as a control (QIAgen). Conditioned medium was collected to measure SEAP activity. For detection of Gαs, Gαq, Gα13, CK2, ADAM9, 10, APP and β-Actin, cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Sodiumdeoxycholate, 0.1% SDS and Complete protease inhibitor tablets (Roche Applied Science)). For detection of MMP9, conditioned medium was cleared from cell debris by centrifugation at 1500 rpm and concentrated with Ultracel-50 centrifugal filter unit (Millipore) according to manufacturer's instructions. For detection of ADAM17, cells were homogenized in 50 mM Tris-HCl pH 8.0 and 150 mM NaCl, 1 µM batimastat and Complete protease inhibitor tablets and centrifuged at 100.000 g for 1 hour at 4°C. Pellets were resuspended in RIPA buffer supplemented with 1 µM batimastat and centrifuged at 100.000 g for 1 hour at 4°C and supernatants containing the membrane fraction were collected. Protein concentrations were determined in each preparation using the Bradford assay (Bio-Rad). Equal amounts of protein were separated with SDS-PAGE in Novex Bis-Tris gels (Invitrogen), transferred to nitrocellulose membranes (Whatman), blocked and probed with antibodies in 3% milk plus 0,1% Tween-20/TBS buffer. Secondary antibody staining was detected with the Renaissance chemiluminescence kit (Perkin Elmer). β-Actin staining was used as a loading control.

Statistical analysis

Differences between multiple means of data with parametric distribution were assessed by ANOVA followed by Tukey-Kramer or Dunnet's post-hoc tests. All experiments were repeated three times. All statistical analysis was performed with GraphPad Prism 5 (GraphPad Software). Optical density of specific immunobands on western blot was quantified using the 1D densitometry package of Aida Image Analyzer v4.27.039.

Results

5-HT4d receptor-stimulated APP shedding requires G protein signaling and is independent of β-arrestin recruitment

In agreement with previous reports which show that activation of the 5-HT4d receptor induces APP shedding in CHO cells [7], we find a significant upregulation of SEAP (secreted alkaline phosphatase) activity in SH-SY5Y human neuroblastoma cells transiently transfected with human 5-HT4d (pcDNA3.1-5-HT4d) and human wild type APP695 coupled to SEAP (pEAK12-AP-APP) following treatment with the 5-HT4 receptor agonists prucalopride or 5-HT. Co-treatment with the 5-HT4 receptor antagonist GR113808 abolishes the increase in AP-APP shedding, demonstrating the specificity of the effect (Figure 1A). Using an alphaLISA specific for sAPPα, we previously demonstrated that the increase in SEAP activity reflects an increase in sAPPα release [9].

thumbnail
Download:
Figure 1. 5-HT4d receptor-stimulated APP shedding requires G protein signaling and is independent of β-arrestin recruitment.

(A) Prucalopride induced sAPPα secretion in SH-SY5Y human neuroblastoma cells is specific for the 5-HT4 receptor. SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride and 5-HT (5-HT4 receptor agonists) in the absence or presence of 1 µM GR113808 (5-HT4 receptor antagonist) or PMA and secretion of sAPPα was analyzed via measuring SEAP. (B) SEAP levels were measured in supernatants of SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d (WT), pcDNA3.1-5-HT4dDRY117/118AAY (DRY) or pcDNA3.1-5-HT4dΔ346 (Δ346) mutants and stimulated with 1 µM prucalopride or 5-HT. (C), (D) and (F) SEAP levels were measured in supernatants of SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d and treated with 1 µM prucalopride or 5-HT in the absence or presence of 100 µM CTB (Gαs inhibitor) (C), 100 µM NF449 (Gαs inhibitor) (D) or 100 µM gallein (Gβγ inhibitor) (F). (E) SEAP levels were measured in SH-SY5Y cells, transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and pcDNAI-Amp-GαsDN or pcDNA3.1 at a ratio of 2∶1∶4, respectively, and treated with 1 µM prucalopride or 5-HT. Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer or Dunnet's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g001

Signaling pathway activation down-stream of the 5-HT4 receptor is mediated through assembly and activation of a heterotrimeric G protein complex. Receptor phosphorylation by GPCR-related kinases (GRKs) limits G protein-mediated signaling and facilitates recruitment of β-arrestins, which mediate receptor internalization and turnover and provide a scaffold for the initiation of signals to several kinases [30]. We used 5-HT4d receptor mutants deficient in either G protein or β-arrestin signaling to distinguish which pathway leads to increased sAPPα secretion upon receptor stimulation. We introduced mutations in the DRY conserved motif, which interrupt coupling to G proteins and prohibit the G protein complex from acquiring an active GTP bound state [31], [32]. Expression of the alanine substitution DRY mutant of the 5-HT4d receptor (pcDNA3.1-5-HT4dDRY117/118AAY) in pEAK12-AP-APP transfected cells resulted in significant downregulation of sAPPα secretion after 5-HT treatment, indicating the putative involvement of G protein signal transduction in 5-HT4d receptor-stimulated release of sAPPα (Figure 1B). Recruitment of β-arrestins to the receptor requires phosphorylation of the C terminus, allowing further internalization and possible signal transduction through the scaffolding of down-stream kinases. We generated a 5-HT4d receptor mutant truncated at amino acid 346 in the C terminus (pcDNA3.1-5-HT4dΔ346), which lacks a conserved sequence of serine and threonine residues required for association of β-arrestins with the receptor after phosphorylation by GRKs. Expression of this mutant in pEAK12-AP-APP transfected cells maintained stimulated induction of sAPPα secretion after prucalopride and 5-HT treatment (Figure 1B). These data suggest that β-arrestins do not contribute to 5-HT4d receptor-induced APP shedding.

In order to confirm that G proteins participate in α-secretase induction, we co-treated pEAK12-AP-APP transfected cells with inhibitors of Gαs, i.e. CTB and NF449. Inhibition of Gαs signaling indeed resulted in significant decrease of induced sAPPα secretion (Figures 1C and D). We also tested a GαsDN mutant, which abolishes all GPCR-mediated G protein-dependent signaling [28]. We found that co-transfection of pcDNAI-Amp-GαsDN with pEAK12-AP-APP and pcDNA3.1-5HT4d inhibited induced sAPPα secretion after prucalopride and 5-HT treatment (Figure 1E), indicating that Gαs activation is involved in 5-HT4d receptor-stimulated α-secretase activity.

The 5-HT4 receptors promiscuously activate several G proteins, i.e. Gαs, Gαq and Gα13, leading to distinct second messenger generation [33]–[35]. We wondered which G protein subunit is specifically responsible for the effect on sAPPα secretion. Therefore, we performed RNAi mediated knock-down of Gαs, Gαq and Gα13 in SH-SY5Y cells and analyzed sAPPα secretion upon 5-HT4d receptor stimulation (Figure S1A). Knock-down efficiency and specificity of siRNA oligonucleotides was confirmed by western blotting (Figures S1B and C). Surprisingly, our data show that single knock-down of each individual Gα subunit equally abolishes 5-HT4d receptor-mediated sAPPα secretion (Figure S1A), suggesting that sAPPα release can be mediated through Gαs, Gαq and Gα13. Such an effect could be explained if there is a requirement for the functional activation of the Gβγ subunits. We used gallein to inhibit Gβγ signaling and found that co-treatment of pEAK12-AP-APP transfected cells with this inhibitor and prucalopride or 5-HT abolished induction of sAPPα secretion (Figure 1F). Altogether, these studies suggest that Gα and Gβγ activation is required for 5-HT4d receptor-stimulated sAPPα release.

5-HT4d receptor-stimulated APP shedding does not involve activation of adenylyl cyclase and cAMP

Gαs and cAMP mediate canonical signaling of 5-HT4 receptors [33]. Therefore, we sought to determine whether, in SH-SY5Y cells, accumulation of cAMP is also necessary for α-secretase activity as previously described for CHO cells [15]. We used the adenylyl cyclase inhibitors SQ22536 and DDA, which potently inhibit increases in cAMP levels (Figure 2C). Interestingly, we found that these inhibitors do not affect prucalopride or 5-HT-stimulated sAPPα release in SH-SY5Y cells (Figures 2A and B). These results suggest that activation of adenylyl cyclase and accumulation of cAMP is not required for 5-HT4d receptor-stimulated APP shedding.

thumbnail
Download:
Figure 2. 5-HT4d receptor-stimulated APP shedding does not require accumulation of cAMP.

(A) and (B) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride or 5-HT (5-HT4 receptor agonists) in the absence or presence of 4 µM SQ22536 (AC inhibitor) (A) or 100 µM DDA (AC inhibitor) (B) and secretion of sAPPα was analyzed via measuring SEAP. (C) Concentration of cAMP was measured in SH-SY5Y cells, transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and pmax-FP-Green-N at a ratio of 5∶4∶1, were treated with 1 µM prucalopride or 5-HT in the absence or presence of 4 µM SQ22536 or 100 µM DDA. Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g002

5-HT4d receptor-stimulated APP shedding requires Src and phospholipase C

Given that 5-HT4d receptor-stimulated APP shedding does not require an elevation in cAMP levels, we sought to determine whether generation of inositol triphosphate (IP3) is involved in 5-HT4d receptor-stimulated sAPPα release. This second messenger is produced by PLC and can be activated either directly down-stream of Gαq and Gβγ or through the Src non-receptor tyrosine kinase (reviewed in [36]). To analyze the contribution of PLC and Src, we co-treated pEAK12-AP-APP and pcDNA3.1-5-HT4d transfected SH-SY5Y cells with the Src inhibitor Bosutinib or the PLC inhibitor D609 and 5-HT4 receptor agonists. In both cases, we observed that APP shedding was abolished compared to control treatment (Figures 3A and B).

thumbnail
Download:
Figure 3. 5-HT4d receptor-stimulated APP shedding requires Src and phospholipase C, but not PKC or calcium.

(A), (B) and (C) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride or 5-HT (5-HT4 receptor agonists) and PMA in the absence or presence of 50 µM Bosutinib (Src inhibitor) (A), 30 µM D609 (PLC inhibitor) (B) or 2 µM GF109203X (PKC inhibitor) (C) and secretion of sAPPα was analyzed via measuring SEAP. Values shown are mean ± SEM of 6 individual wells and were normalized towards vehicle control. (D) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were loaded with Fluo-4 NW mix and fluorescence of the calcium-sensitive dye in each well was recorded at the baseline (F0) and after stimulation with 1 µM prucalopride, 30 µM ATP (purinergic ionotropic receptors agonist), 20 µM Ionomycin (calcium ionophore) or DMSO (F). Calcium response shown is a ratio of maximum fluorescence intensity at 40 sec to baseline fluorescence (F/F0). Values shown are mean ± SEM of 2 individual wells and were normalized to vehicle control. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g003

PLC cleaves phosphatidylinositol 4,5-bisphosphate into IP3 and diacylglycerol, resulting in mobilization of intracellular calcium and activation of several downstream effector proteins including PKC [37]. In addition, several studies suggest that calcium and PKC signaling can activate α-secretase shedding of APP [38], [39]. Co-treatment of transiently transfected SH-SY5Y cells with the PKC inhibitor GF109203X did not induce sAPPα secretion after 5-HT4d receptor stimulation. In contrast, direct activation of PKC with PMA induced sAPPα, but this induction was inhibited with GF109203X showing that the inhibitor was functional (Figure 3C). Similarly, prucalopride did not significantly alter extracellular calcium influx in SH-SY5Y cells, in contrast to ionomycin and ATP; two positive controls that prove assay functionality (Figure 3D). Taken together these data suggest that Src and PLC, but not PKC or calcium signaling, contribute to 5-HT4d receptor-induced APP shedding.

5-HT4d receptor-stimulated APP shedding requires inositol polyphosphates and casein kinase 2

IP3 can be further phosphorylated by inositol 1,4,5-triphosphate 3-kinase (IP3K) and inositol polyphosphate multikinase (IPMK) to generate inositol polyphosphates (IP4, IP5 and IP6). These molecules recently emerged as versatile second messengers with an increasing number of cellular functions [40]. We tested the IP3K inhibitor and the IPMK inhibitor CGA in transfected SH-SY5Y cells and found that prucalopride or 5-HT-stimulated α-secretase activity depends on the generation of these inositol polyphosphates (Figures 4A and B). The reported literature suggests that IP4 and/or IP6 can activate CK2 in vitro [41]. In cells, Wnt3a can induce IP5 generation which then activates CK2 [42]. Inhibition of CK2 activity with TBB in pcDNA3.1-5-HT4d receptor and pEAK12-AP-APP expressing SH-SY5Y cells stimulated with prucalopride or 5-HT led to a decrease in sAPPα down to baseline levels (Figure 4C), suggesting that CK2 is involved in 5-HT4d receptor-stimulated APP shedding. In addition, we found that co-transfection of CK2 siRNA completely abolished stimulated APP shedding in SH-SY5Y cells treated with prucalopride or 5-HT (Figures 4D, E and F). These results demonstrate that 5-HT4d receptor-stimulated APP shedding requires inositol polyphosphates and CK2.

thumbnail
Download:
Figure 4. 5-HT4d receptor-stimulated APP shedding requires inositol polyphosphates and casein kinase 2.

(A), (B) and (C) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride or 5-HT (5-HT4 receptor agonists) in the absence or presence of 20 µM IP3K inhibitor (A), 80 µM CGA (IPMK inhibitor) (B) or 2.5 µM TBB (CK2 inhibitor) (C) and secretion of sAPPα was analyzed via measuring SEAP. (D) SEAP levels were measured in supernatants of SH-SY5Y cells, co-transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and 3 nM siRNA for knock-down of CK2 and treated with 1 µM prucalopride. (E) Cell lysates of (D) were analyzed for CK2 expression levels by western blotting. (F) Quantification of experiments in (E). Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g004

ADAM9, ADAM10, ADAM17 and MMP9 are not responsible for 5-HT4d receptor-stimulated α-secretase activity

Several enzymes of the ADAM and MMP family, such as ADAM9, 10, 17 and MMP9, are suggested candidate proteins responsible for inducible shedding of APP (reviewed in [43]). To determine the relative contribution of the metalloproteinases in 5-HT4d receptor-stimulated sAPPα release, we first analyzed expression levels of ADAM9, 10, 17 and MMP9 in SH-SY5Y cells. Expression of ADAM9, 10, 17 and MMP9 was not changed after prucalopride treatment of pEAK12-AP-APP transfected SH-SY5Y cells (Figures S3A and B). To test whether a metalloproteinase would be responsible for induced α-secretase activity, we treated the cells with non-toxic concentrations of the broad spectrum metalloproteinase inhibitor GM6001 (dose response curve shown in Figure S4). Treatment with GM6001 abolished induction of sAPPα secretion (Figure 5A), confirming that a metalloproteinase is indeed responsible for 5-HT4d receptor-stimulated sAPPα release. To identify the 5-HT4d receptor-stimulated α-secretase, we performed RNAi knock-down of the candidate α-secretases. We found that induction of sAPPα release was preserved after prucalopride treatment and single knock-down of ADAM9, 10, 17 or MMP9 (Figure 5B). The efficiency of the downregulation was between 85–95% as documented by western blot analysis (Figures 5C and D). These data suggest that ADAM9, 10, 17 or MMP9 are not responsible for 5-HT4d receptor-mediated inducible α-secretase activity in SH-SY5Y cells. We also analyzed constitutive sAPPα secretion upon ADAM10 knock-down in non-treated cells and confirmed that ADAM10 acts as the constitutive α-secretase of APP in our experimental conditions (data not shown).

thumbnail
Download:
Figure 5. Single knock-down of ADAM9, ADAM10, ADAM17 and MMP9 does not affect 5-HT4d receptor-stimulated APP shedding.

(A) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride or 5-HT (5-HT4 receptor agonists) in the absence or presence of 80 µM GM6001 (metalloproteinases inhibitor) and secretion of sAPPα was analyzed via measuring SEAP. (B) SEAP levels were measured in supernatants of SH-SY5Y cells, co-transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and 3 nM siRNA for knock-down of ADAM9 (A9), ADAM10 (A10), ADAM17 (A17) and MMP9 and treated with 1 µM prucalopride. (C) Cell lysates of (B) were analyzed for protein expression of ADAM9, 10, 17 and MMP9 by western blotting. The ADAM10 and ADAM17 immature precursor proteins are indicated by an x, whereas the mature catalytically active forms are indicated by an xx for ADAM9, 17 and MMP9. The immature ADAM9 and the mature ADAM10 proteins were not visible. (D) Quantification of experiments in (C). Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g005

Metalloproteinases are notorious for their functional redundancy between family members. To test whether more than one candidate metalloproteinase could be responsible for induction of α-secretase activity, we treated transfected SH-SY5Y cells with combinations of RNAi directed at ADAM9 and 10, ADAM9 and 17, ADAM10 and 17 (Figure 6A). We observed no change in sAPPα secretion upon 5-HT4d receptor stimulation under any of these conditions. Moreover, knock-down of all four candidate metalloproteinases, i.e. ADAM9, 10, 17 and MMP9, still resulted in induction of sAPPα release after 5-HT4d receptor activation (Figure 6B). The levels of C-terminal fragments generated by the cleavage of APP at β- and β′-sites remained unchanged after the knock-down of ADAM9, 10, 17 and MMP9, suggesting that β-secretase activity was not affected by reduced expression levels of these metalloproteinases (Figures S5A and B). We used western blotting to confirm the efficiency and specificity of RNAi mediated downregulation (Figures 6C and D). Notice also the strong upregulation of MMP9 expression when ADAM9, 10 and 17 are downregulated, while single MMP9 knock-down did not affect 5-HT4d receptor-induced sAPPα secretion. Altogether, our data suggest that an unidentified GM6001-sensitive metalloproteinase participates in the regulated cleavage of APP upon 5-HT4d receptor stimulation (Figure 6B).

thumbnail
Download:
Figure 6. Combined knock-down of ADAM9, ADAM10, ADAM17 and MMP9 does not affect 5-HT4d receptor-stimulated APP shedding.

(A) and (B) SH-SY5Y cells, co-transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4 and combinations of 3 nM siRNA for knock-down of ADAM9 (A9) and ADAM10 (A10), ADAM9 (A9) and ADAM17 (A17), ADAM10 (A10) and ADAM17 (A17) in (A) or ADAM9, 10 and 17 or ADAM9, 10, 17 and MMP9 in (B), were treated with 1 µM prucalopride (5-HT4 receptor agonist) in the absence or presence of 80 µM GM6001 (metalloproteinases inhibitor) (B) and secretion of sAPPα was analyzed via measuring SEAP. (C) Cell lysates of experiments in (A) and (B) were analyzed for protein expression of ADAM9, 10, 17 and MMP9 by western blotting. ADAM10 and ADAM17 immature precursor proteins are indicated by an x, whereas the mature catalytically active forms are indicated by an xx for ADAM9, 17 and MMP9. The immature ADAM9 and the mature ADAM10 proteins were not visible. (D) Quantification of experiments in (C). Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.g006

Discussion

In this report, we examined the signaling pathway that leads to α-secretase induction after 5-HT4d receptor stimulation in the human neuroblastoma SH-SY5Y cell line. We present here a previously uncharacterized signaling pathway involved in the mediation of 5-HT4d receptor-induced α-secretase activity (Figure 7). The characterization of this pathway was based on a combination of pharmacological, siRNA and site-directed mutagenesis experiments. Our data indicate that PLC is essential for α-secretase activation following 5-HT4d stimulation. This effect is dependent on Gα and Gβγ recruitment and signaling downstream of the 5-HT4d receptor. Src tyrosine kinase acts as an intermediate molecule, mediating PLC activation and inositol triphosphate production. The latter is converted by multiple kinases to inositol polyphosphates, which activate CK2. Downstream of CK2, a yet unknown mechanism of α-secretase activation is triggered. The 5-HT4d receptor-induced α-secretase activity could not be ascribed to any known candidate α-secretase (ADAM9, 10, 17 and MMP9) in the SH-SY5Y cells, which has hampered delineation of the final step regulating 5-HT4d receptor-stimulated sAPPα release.

thumbnail
Download:
Figure 7. Schematic representation of the proposed 5-HT4d receptor-stimulated signaling pathway leading to increased sAPPα production.

The proteins involved in 5-HT4d receptor-mediated non-amyloidogenic APP shedding are shown with green circles while orange circles and red characters indicate proteins or second messengers that were tested but were ineffective in modulating 5-HT4d receptor-stimulated sAPPα release. The dotted lines with the question marks indicate remaining areas of investigation for further elucidation of the molecular mechanism of α-secretase activation. cAMP-dependent pathway of α-secretase induction was previously reported and is depicted as a plausible way for 5-HT4d receptor-mediated sAPPα release [15].

https://doi.org/10.1371/journal.pone.0087014.g007

We found also that β-arrestin signaling did not contribute to α-secretase activity upon 5-HT4d receptor stimulation as the mutant receptor deficient in β-arrestin recruitment maintained the ability to stimulate sAPPα secretion after agonist treatment (Figure 1B). Interestingly, β-arrestins have recently emerged as regulators of Aβ generation downstream of the β2-adrenergic receptor and GPR3, independently of G protein activation [44], [45]. In these studies, β-arrestins appear to bind to the Aph1 subunit of the γ-secretase complex, affecting complex localization and thereby increasing the catalytic activity of the γ-secretase complex. Our work suggests that different signaling pathways regulate α- and γ-secretase activity as we find that G proteins are indispensable for 5-HT4d receptor-stimulated α-secretase activity, while they are not involved in the γ-secretase regulation by GPCRs. Indeed, several molecules that are activated downstream of G proteins are proposed to regulate α-site APP processing, e.g. PKC, PKA, MAPK, ERK and PI3K (reviewed in [46]).

Originally the 5-HT4 receptor was shown to couple to Gαs [17], [33]–[35], [47]. We show here that the Gαs, Gαq and Gα13 subunits are equally required for sustainable α-secretase activity after 5-HT4d receptor stimulation (Figure S1A). We did not observe functional compensation between the different Gα subunits, even though protein expression was modulated in a reciprocal manner for Gαs and Gαq (Figure S2). These results were unexpected and we speculate that parallel signaling initiated by the different Gα subunits or a certain threshold level of G proteins would be required to transduce the agonist-dependent signal. In those views reduction of the level of one of subunit could already abolish the signal. Our results also show that the signal relies on the association with the Gβγ subunits as a converging signal transduction mediator (Figure 1F). Similar observations have been previously made for PLC activation by G proteins in vitro. IP3 production was more efficient in the presence of the G protein trimeric complex than in separate preparations of either Gαq or Gβγ alone [48], [49]. Interestingly, we also observe a reduction in constitutive sAPPα release after the knock-down of Gαs, Gαq and Gα13 (Figure S1A). These data suggest a dominant negative effect of G proteins inhibition on constitutive α-secretase activity, which may be mediated by additional GPCRs besides the 5-HT4d receptor.

5-HT4 receptor coupling to different G proteins suggests several possibilities for downstream signal transduction. Several reports describe a PKA-independent and cAMP-dependent α-secretase activation following 5-HT4d receptor stimulation [7], [50], [51]. In CHO cells, sAPPα release is regulated by Epac1, which promotes small GTPases Rap1 dependent Rac activation [15]. However, we find that AC and cAMP accumulation are not required for 5-HT4d receptor-induced APP shedding under our experimental conditions (Figure 2). Differences in the cellular systems, a human neuronal cell line versus a Chinese hamster ovary cell line, could explain the discrepancy between the studies. We then found that IP3 generation through Src and PLC activation contributes to 5-HT4d receptor-induced α-secretase activity (Figure 3). PLC is also an important component of the α-secretase activation pathway through Gαq coupled GPCRs, e.g. mGluR1 and mGluR5 [52], M1 and M3 [53], 5-HT2a and 5-HT2c [54] and thus a point of convergence for several transduction pathways activating α-secretase.

Investigations of the cerebral cortex and cerebellum of AD-affected individuals reveal disturbed G protein signal transduction compared to control patients [55]. In accordance, the phosphoinositide hydrolysis pathway is also altered in AD because of reduced levels of phosphatidylinositide 3-kinase and disturbed agonist and G protein regulation of PLC [56], [57]. It is proposed that 5-HT4 receptor stimulation could counteract such detrimental changes. We show here that the 5-HT4d receptor indeed induces IP3K and IPMK mediated IP3 conversion to inositol polyphosphates and that these contribute to the non-amyloidogenic pathway of APP processing (Figure 4). This effect is mediated through the activation of CK2, which was recently identified to be downstream of the cholinergic receptors in a pathway of α-secretase induction [58]. As activation of the 5-HT4 receptor can increase acetylcholine levels in the brain [6], [13] and we need 24 hours to obtain a significant induction of the α-secretase, an indirect mechanism through upregulation of acetylcholine could play a role. As our cells are of the dopaminergic origin, we think this possibility is rather unlikely. However, we cannot rule out that other indirect mechanisms are playing a role in the 5-HT4d receptor-mediated α-secretase induction.

To understand the molecular mechanism of α-secretase activation downstream of the 5-HT4d receptor, we investigated the contribution of ADAM9, 10, 17 and MMP9 in the regulation of APP processing. Previously, regulated α-secretase activity was partially attributed to MMP9, whose expression levels increased after 5-HT4d receptor stimulation in APP-overexpressing H4 human neuroglioma cells [59]. However, in our cellular system, expression levels of the investigated proteinases do not change (Figure S3) and specific protein downregulation suggests that a different metalloproteinase, besides the major candidate α-secretases ADAM9, 10, 17 and MMP9, contributes to 5-HT4d receptor-induced sAPPα release (Figures 5 and 6). Indeed, ADAM10 was not responsible for the 5-HT4d receptor-dependent induction of sAPPα release through the cAMP/Epac pathway [21]. At this moment, we cannot rule out that the remaining protein expression of these four major α-secretases contribute to the preserved inducible α-secretase activity. Our data are consistent with the present view of different proteases contributing to regulated APP processing as previously reported for the M1 receptor, the insulin-like growth factor-1 receptor and the purinergic P2Y2 and P2X7 receptors [23], [60]–[62]. To identify the metalloproteinase(s) responsible for induced α-secretase activity we were reluctant to use differences in susceptibility to GM6001 because we were working with overexpression conditions. This would require a large-scale RNAi knock-down study but is beyond the scope of the current manuscript.

In conclusion, our studies show the complexity of α-secretase regulation upon 5-HT4d receptor stimulation. Taking into consideration that receptor modulation of signaling pathways depends on the cellular context and that recombinant overexpression and RNA interference may reveal cell type specific results, a relevant physiological system should be used for the confirmation of the identified signaling pathway. Clinical trials of agonists targeting 5-HT4 serotonergic and M1 muscarinic receptors will provide validation of α-secretase activation as a therapeutic approach for the treatment of AD. We report here that PLC dependent production of IP3 and CK2 activation are important mediators of the 5-HT4d receptor signaling that enhance the non-amyloidogenic processing of APP. These proteins can also participate in signaling downstream of muscarinic receptors, suggesting the possibility of a common pathway for α-secretase activation through GPCRs. Finally, our data will also aid with the development of 5-HT4 receptor agonists as therapeutics for neurodegenerative or psychiatric disorders and allow for a better understanding of potential risks associated with these drugs.

Supporting Information

Figure S1.

5-HT4d receptor-stimulated APP shedding requires the G proteins Gαs, Gαq and Gα13. (A) SEAP levels were measured in supernatants of SH-SY5Y cells, co-transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and 3 nM siRNA for knock-down of Gαs, Gαq and Gα13 and treated with 1 µM prucalopride (5-HT4 receptor agonist). (B) Cell lysates of (A) were analyzed for protein expression of Gαs, Gαq and Gα13 by western blotting. (C) Quantification of experiments in (B). Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.s001

(TIF)

Figure S2.

Knock-down of Gαs and Gαq but not Gα13 alters protein expression of the G protein family. (A) SH-SY5Y cells, transfected with 3 nM siRNA for knock-down of Gαs, Gαq and Gα13, were harvested and expression levels of G proteins were analyzed. (B) Quantification of experiments in (A). Values shown are mean ± SEM of 2 individual wells and were normalized to vehicle control. ** P<0.01, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.s002

(TIF)

Figure S3.

Expression levels of major candidate α-secretases and APP do not change upon 5-HT4d receptor stimulation. (A) SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride (5-HT4 receptor agonist) and collected to analyze protein expression of ADAM9, 10, 17, MMP9 and APP by western blotting. ADAM10 and ADAM17 immature precursor proteins are indicated by an x, whereas the mature catalytically active forms are indicated by an xx for ADAM9, 17 and MMP9. The immature ADAM9 and the mature ADAM10 proteins were not visible. (B) Quantification of experiments in (A). Values shown are mean ± SEM of 2 individual wells and were normalized to vehicle control.

https://doi.org/10.1371/journal.pone.0087014.s003

(TIF)

Figure S4.

The metalloproteinase inhibitor GM6001 can inhibit secretion of sAPPα upon 5-HT4d receptor stimulation. SH-SY5Y cells, transfected with pEAK12-AP-APP and pcDNA3.1-5-HT4d, were treated with 1 µM prucalopride or 5-HT in the absence or presence of different concentrations of GM6001 and secretion of sAPPα was analyzed via measuring SEAP. Values shown are mean ± SEM of 6 individual wells and are normalized towards vehicle control. ** P<0.01, *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test.

https://doi.org/10.1371/journal.pone.0087014.s004

(TIF)

Figure S5.

Knock-down of ADAM9, 10, 17 and MMP9 does not affect the pattern of CTFs generated by the 5-HT4d receptor-stimulated α-secretase activity. (A) SH-SY5Y cells, co-transfected with pEAK12-AP-APP, pcDNA3.1-5-HT4d and combinations of 3 nM siRNA for knock-down of ADAM9 (A9), ADAM10 (A10) and ADAM17 (A17) or ADAM9, 10, 17 and MMP9, were treated with 1 µM prucalopride (5-HT4 receptor agonist) and secretion of sAPPα was analyzed via measuring SEAP. Values shown are mean ± SEM of 6 individual wells and were normalized to vehicle control. *** P<0.001, one-way ANOVA with Tukey-Kramer's post-hoc test. (B) Cell lysates of the experiment in (A) were analyzed for the levels of different APP C-terminal fragments (CTFs) were analyzed by western blotting using B63 antibody (16% Tricine SDS-PAGE).

https://doi.org/10.1371/journal.pone.0087014.s005

(TIF)

Table S1.

https://doi.org/10.1371/journal.pone.0087014.s006

(DOCX)

Acknowledgments

We are grateful to Catherine Berlot for providing the pcDNAI-Amp-GαsDN plasmid. We thank Joris De Mayer and Jan Schuurkes (Shire-Movetis, NV, Turnhout, Belgium) for providing us with prucalopride. We thank Stefan F. Lichtenthaler (German Center for Neurodegenerative Diseases (DZNE), Munich, Germany) for providing us with the pEAK12-AP-APP plasmid.

Author Contributions

Conceived and designed the experiments: AAP AT BDS IT. Performed the experiments: AAP. Analyzed the data: AAP AT BDS IT. Contributed reagents/materials/analysis tools: AAP AT BDS IT. Wrote the paper: AAP AT BDS IT.

References

  1. 1. De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90: 465–494.
  2. 2. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456–1464.
  3. 3. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142: 320–332.
  4. 4. Bockaert J, Claeysen S, Compan V, Dumuis A (2008) 5-HT(4) receptors: history, molecular pharmacology and brain functions. Neuropharmacology 55: 922–931.
  5. 5. Spencer JP, Brown JT, Richardson JC, Medhurst AD, Sehmi SS, et al. (2004) Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease. Neuroscience 129: 49–54.
  6. 6. Matsumoto M, Togashi H, Mori K, Ueno K, Ohashi S, et al. (2001) Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 296: 676–682.
  7. 7. Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc'h F (2001) The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem 276: 44881–44888.
  8. 8. Cho S, Hu Y (2007) Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 203: 274–278.
  9. 9. Tesseur I, Pimenova AA, Lo AC, Ciesielska M, Lichtenthaler SF, et al. (2013) Chronic 5-HT4 receptor activation decreases Abeta production and deposition in hAPP/PS1 mice. Neurobiol Aging 34: 1779–1789.
  10. 10. Cachard-Chastel M, Lezoualc'h F, Dewachter I, Delomenie C, Croes S, et al. (2007) 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br J Pharmacol 150: 883–892.
  11. 11. Shen F, Smith JA, Chang R, Bourdet DL, Tsuruda PR, et al. (2011) 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 61: 69–79.
  12. 12. Micale V, Leggio GM, Mazzola C, Drago F (2006) Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia. Brain Res 1121: 207–215.
  13. 13. Consolo S, Arnaboldi S, Giorgi S, Russi G, Ladinsky H (1994) 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 5: 1230–1232.
  14. 14. Farlow MR, Cummings JL (2007) Effective pharmacologic management of Alzheimer's disease. Am J Med 120: 388–397.
  15. 15. Maillet M, Robert SJ, Cacquevel M, Gastineau M, Vivien D, et al. (2003) Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat Cell Biol 5: 633–639.
  16. 16. Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, et al. (2007) 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 18: 1979–1991.
  17. 17. Contesse V, Hamel C, Lefebvre H, Dumuis A, Vaudry H, et al. (1996) Activation of 5-hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5-hydroxytryptamine-induced steroid secretion. Mol Pharmacol 49: 481–493.
  18. 18. Ouadid H, Seguin J, Richard S, Chaptal PA, Nargeot J (1991) Properties and Modulation of Ca channels in adult human atrial cells. J Mol Cell Cardiol 23: 41–54.
  19. 19. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, et al. (2010) The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 30: 4833–4844.
  20. 20. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, et al. (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29: 3020–3032.
  21. 21. Cochet M, Donneger R, Cassier E, Gaven F, Lichtenthaler SF, et al. (2013) 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci 4: 130–140.
  22. 22. Le Gall SM, Bobe P, Reiss K, Horiuchi K, Niu XD, et al. (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 20: 1785–1794.
  23. 23. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, et al. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49: 671–682.
  24. 24. Jefferson T, Causevic M, auf dem Keller U, Schilling O, Isbert S, et al. (2011) Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem 286: 27741–27750.
  25. 25. Ahmad M, Takino T, Miyamori H, Yoshizaki T, Furukawa M, et al. (2006) Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. J Biochem 139: 517–526.
  26. 26. Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M (2010) An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 20: 1069–1082.
  27. 27. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, et al. (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11: 2615–2624.
  28. 28. Berlot CH (2002) A highly effective dominant negative alpha s construct containing mutations that affect distinct functions inhibits multiple Gs-coupled receptor signaling pathways. J Biol Chem 277: 21080–21085.
  29. 29. Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, et al. (2003) The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278: 48713–48719.
  30. 30. Reiter E, Lefkowitz RJ (2006) GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17: 159–165.
  31. 31. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, et al. (2012) Action of molecular switches in GPCRs–theoretical and experimental studies. Curr Med Chem 19: 1090–1109.
  32. 32. Rovati GE, Capra V, Neubig RR (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959–964.
  33. 33. Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J (1988) A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34: 880–887.
  34. 34. Chang WC, Ng JK, Nguyen T, Pellissier L, Claeysen S, et al. (2007) Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS One 2: e1317.
  35. 35. Ponimaskin EG, Profirovic J, Vaiskunaite R, Richter DW, Voyno-Yasenetskaya TA (2002) 5-Hydroxytryptamine 4(a) receptor is coupled to the Galpha subunit of heterotrimeric G13 protein. J Biol Chem 277: 20812–20819.
  36. 36. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70: 281–312.
  37. 37. Berridge MJ (1993) Inositol trisphosphate and calcium signalling. Nature 361: 315–325.
  38. 38. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P (1994) Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci U S A 91: 4489–4493.
  39. 39. LeBlanc AC, Koutroumanis M, Goodyer CG (1998) Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures. J Neurosci 18: 2907–2913.
  40. 40. Shears SB (1998) The versatility of inositol phosphates as cellular signals. Biochim Biophys Acta 1436: 49–67.
  41. 41. Solyakov L, Cain K, Tracey BM, Jukes R, Riley AM, et al. (2004) Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem 279: 43403–43410.
  42. 42. Gao Y, Wang HY (2007) Inositol pentakisphosphate mediates Wnt/beta-catenin signaling. J Biol Chem 282: 26490–26502.
  43. 43. Vingtdeux V, Marambaud P (2012) Identification and biology of alpha-secretase. J Neurochem 120 Suppl 1: 34–45.
  44. 44. Thathiah A, Horre K, Snellinx A, Vandewyer E, Huang Y, et al. (2013) beta-arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer's disease. Nat Med 19: 43–49.
  45. 45. Liu X, Zhao X, Zeng X, Bossers K, Swaab DF, et al. (2013) beta-arrestin1 regulates gamma-secretase complex assembly and modulates amyloid-beta pathology. Cell Res 23: 351–365.
  46. 46. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 14: 2848–2864.
  47. 47. Robert S, Maillet M, Morel E, Launay JM, Fischmeister R, et al. (2005) Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. FEBS Lett 579: 1136–1142.
  48. 48. Smrcka AV, Sternweis PC (1993) Regulation of purified subtypes of phosphatidylinositol-specific phospholipase C beta by G protein alpha and beta gamma subunits. J Biol Chem 268: 9667–9674.
  49. 49. Kozasa T, Hepler JR, Smrcka AV, Simon MI, Rhee SG, et al. (1993) Purification and characterization of recombinant G16 alpha from Sf9 cells: activation of purified phospholipase C isozymes by G-protein alpha subunits. Proc Natl Acad Sci U S A 90: 9176–9180.
  50. 50. Lezoualc'h F, Robert SJ (2003) The serotonin 5-HT4 receptor and the amyloid precursor protein processing. Exp Gerontol 38: 159–166.
  51. 51. Marambaud P, Ancolio K, Alves da Costa C, Checler F (1999) Effect of protein kinase A inhibitors on the production of Abeta40 and Abeta42 by human cells expressing normal and Alzheimer's disease-linked mutated betaAPP and presenilin 1. Br J Pharmacol 126: 1186–1190.
  52. 52. Lee RK, Wurtman RJ, Cox AJ, Nitsch RM (1995) Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci U S A 92: 8083–8087.
  53. 53. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304–307.
  54. 54. Nitsch RM, Deng M, Growdon JH, Wurtman RJ (1996) Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 271: 4188–4194.
  55. 55. Lumbreras M, Baamonde C, Martinez-Cue C, Lubec G, Cairns N, et al. (2006) Brain G protein-dependent signaling pathways in Down syndrome and Alzheimer's disease. Amino Acids 31: 449–456.
  56. 56. Jolles J, Bothmer J, Markerink M, Ravid R (1992) Phosphatidylinositol kinase is reduced in Alzheimer's disease. J Neurochem 58: 2326–2329.
  57. 57. Albasanz JL, Dalfo E, Ferrer I, Martin M (2005) Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol Dis 20: 685–693.
  58. 58. Lenzken SC, Stanga S, Lanni C, De Leonardis F, Govoni S, et al. (2010) Recruitment of casein kinase 2 is involved in AbetaPP processing following cholinergic stimulation. J Alzheimers Dis 20: 1133–1141.
  59. 59. Hashimoto G, Sakurai M, Teich AF, Saeed F, Aziz F, et al. (2012) 5-HT(4) receptor stimulation leads to soluble AbetaPPalpha production through MMP-9 upregulation. J Alzheimers Dis 32: 437–445.
  60. 60. Jacobsen KT, Adlerz L, Multhaup G, Iverfeldt K (2010) Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-beta precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J Biol Chem 285: 10223–10231.
  61. 61. Camden JM, Schrader AM, Camden RE, Gonzalez FA, Erb L, et al. (2005) P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J Biol Chem 280: 18696–18702.
  62. 62. Delarasse C, Auger R, Gonnord P, Fontaine B, Kanellopoulos JM (2010) The purinergic receptor P2X7 triggers alpha-secretase-dependent processing of the amyloid precursor protein. J Biol Chem 286: 2596–2606.
  63. 63. Ansanay H, Sebben M, Bockaert J, Dumuis A (1996) Pharmacological comparison between [3H]GR 113808 binding sites and functional 5-HT4 receptors in neurons. Eur J Pharmacol 298: 165–174.
  64. 64. Van den Wyngaert I, Gommeren W, Verhasselt P, Jurzak M, Leysen J, et al. (1997) Cloning and expression of a human serotonin 5-HT4 receptor cDNA. J Neurochem 69: 1810–1819.
  65. 65. Milligan G, Unson CG, Wakelam MJ (1989) Cholera toxin treatment produces down-regulation of the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs). Biochem J 262: 643–649.
  66. 66. Shen KF, Crain SM (1990) Cholera toxin-B subunit blocks excitatory effects of opioids on sensory neuron action potentials indicating that GM1 ganglioside may regulate Gs-linked opioid receptor functions. Brain Res 531: 1–7.
  67. 67. Hohenegger M, Waldhoer M, Beindl W, Boing B, Kreimeyer A, et al. (1998) Gsalpha-selective G protein antagonists. Proc Natl Acad Sci U S A 95: 346–351.
  68. 68. Lehmann DM, Seneviratne AM, Smrcka AV (2008) Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol Pharmacol 73: 410–418.
  69. 69. Harris DN, Asaad MM, Phillips MB, Goldenberg HJ, Antonaccio MJ (1979) Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res 5: 125–134.
  70. 70. Gao Y, Usha Raj J (2002) Effects of SQ 22536, an adenylyl cyclase inhibitor, on isoproterenol-induced cyclic AMP elevation and relaxation in newborn ovine pulmonary veins. Eur J Pharmacol 436: 227–233.
  71. 71. Onoda JM, Braun T, Wrenn SM Jr (1987) Characterization of the purine-reactive site of the rat testis cytosolic adenylate cyclase. Biochem Pharmacol 36: 1907–1912.
  72. 72. Legrand AB, Narayanan TK, Ryan US, Aronstam RS, Catravas JD (1990) Effects of adenosine and analogs on adenylate cyclase activity in cultured bovine aortic endothelial cells. Biochem Pharmacol 40: 1103–1109.
  73. 73. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, et al. (2006) SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66: 2279–2286.
  74. 74. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, et al. (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7: 1185–1194.
  75. 75. Amtmann E (1996) The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res 22: 287–294.
  76. 76. Tschaikowsky K, Meisner M, Schonhuber F, Rugheimer E (1994) Induction of nitric oxide synthase activity in phagocytic cells inhibited by tricyclodecan-9-yl-xanthogenate (D609). Br J Pharmacol 113: 664–668.
  77. 77. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, et al. (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268: 9194–9197.
  78. 78. Jacobson PB, Kuchera SL, Metz A, Schachtele C, Imre K, et al. (1995) Anti-inflammatory properties of Go 6850: a selective inhibitor of protein kinase C. J Pharmacol Exp Ther 275: 995–1002.
  79. 79. Chang YT, Choi G, Bae YS, Burdett M, Moon HS, et al. (2002) Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem 3: 897–901.
  80. 80. Mayr GW, Windhorst S, Hillemeier K (2005) Antiproliferative plant and synthetic polyphenolics are specific inhibitors of vertebrate inositol-1,4,5-trisphosphate 3-kinases and inositol polyphosphate multikinase. J Biol Chem 280: 13229–13240.
  81. 81. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, et al. (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Lett 496: 44–48.
  82. 82. Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, et al. (2004) Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 47: 6239–6247.
  83. 83. Zien P, Duncan JS, Skierski J, Bretner M, Litchfield DW, et al. (2005) Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim Biophys Acta 1754: 271–280.
  84. 84. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, et al. (1994) Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 732: 315–323.
  85. 85. Moss ML, Rasmussen FH (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 366: 144–148.